Toutes les études
RecrutementPHASE3INTERVENTIONNEL

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

This study is investigating a medicine called ritlecitinib for treating alopecia areata, a condition causing hair loss. Ritlecitinib is already approved in some countries at a 50mg dose. This study will compare that dose with a higher 100mg dose to see if it's also safe and effective. Researchers want to find out if the 100mg dose helps hair grow back and if it has any side effects. Participants, aged 12 and older with significant scalp hair loss due to alopecia areata, will take part. They will be randomly assigned to receive one of the doses, or a dummy pill (placebo), and will be observed for about 13 months with regular check-ups.

En un coup d'œil

Statut
Recrutement
Phase
PHASE3
Sponsor
Pfizer
Objectif d'inscription
674
Démarrer
01 Apr 2025
Achèvement estimé
19 Mar 2028

De quoi parle cette étude ?

Alopecia areata is a common condition where the immune system mistakenly attacks hair follicles, leading to hair loss on the scalp, face, and sometimes other parts of the body. While there are some treatments available, researchers are always looking for new and effective options.

This particular study is focusing on a medicine called ritlecitinib. It's designed to help calm down the immune system's overreaction that causes hair loss. A 50mg dose of ritlecitinib is already used in many countries for severe alopecia areata in people aged 12 and above. Now, doctors want to see if a higher 100mg dose might be even more effective, while still being safe.

The main goal of this study is to compare the 50mg and 100mg doses of ritlecitinib. They want to check how well both doses work in helping hair grow back, as well as keeping a close eye on any potential side effects. By carefully studying these two doses, researchers hope to better understand the best way to use ritlecitinib to help people living with alopecia areata.

Points clés

  • This study evaluates two doses (50mg and 100mg) of ritlecitinib for alopecia areata.
  • Ritlecitinib aims to help hair regrowth by addressing the immune system.
  • Participants will be aged 12 and older with significant scalp hair loss.
  • The study lasts about 13 months with regular clinic visits.
  • You will be randomly assigned to receive ritlecitinib or a placebo.
  • Participation includes various health checks and questionnaires.

Qui peut être éligible ?

To join this study, you need to be at least 12 years old and have a clear diagnosis of alopecia areata. This means your doctor has confirmed your hair loss is due to this specific condition, and not something else. You must also have lost at least half of the hair on your scalp.

It's important that your hair loss specifically due to alopecia areata and not another medical issue. Also, your current episode of hair loss shouldn't have started more than 10 years ago. You must be willing to stop any other alopecia areata treatments you're currently using while you're in the study.

There are also some reasons why you might not be able to join. For example, if you have other conditions that cause hair loss, a history of serious allergic reactions to similar medicines, or certain infections, you might not be eligible. The study team will discuss all these details with you thoroughly to make sure taking part is safe and suitable for you.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Are you 12 years of age or older?
  2. Have you been diagnosed with alopecia areata?
  3. Have you lost 50% or more of the hair on your scalp?
  4. Is your current hair loss episode 10 years old or less?
  5. Are you willing to stop any other alopecia areata treatments if you join?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you join this study, you'll be involved for about 13 months. During this time, you'll be asked to visit the study clinic up to 9 times. When you join, you'll be randomly assigned, like drawing names out of a hat, to receive one of the two doses of ritlecitinib (50mg or 100mg), or a dummy pill called a placebo. You'll take your assigned medicine by mouth once a day.

During your visits, the study team will carry out several checks. These will include assessing your hair loss, having physical examinations, hearing tests, and blood tests. You might also have an X-ray and an ECG (a test that checks your heart's electrical activity). They'll take photographs of your scalp and eyes to track any changes. You'll also be asked to fill in some questionnaires about your alopecia areata and how you're feeling.

Risques et avantages potentiels

Taking part in a clinical study can offer potential benefits, such as access to a new treatment before it's widely available and contributing to medical knowledge that could help others. However, there are also potential risks, as with any medication. You might experience side effects from the study medicine, or the treatment might not work for you. There will also be appointments and tests that take up your time. It's very important to remember that you can stop participating in the study at any time, for any reason, without it affecting your usual medical care.

Locations (148)

  • The Kirklin Clinic of UAB Hospital (Radiology)
    Code postal vérifié
    Birmingham, États-Unis· Recrutement
  • University of Alabama at Birmingham Faculty Office Towers (Regulatory)
    Code postal vérifié
    Birmingham, États-Unis· Recrutement
  • Université de l'Alabama à Birmingham
    Code postal vérifié
    Birmingham, États-Unis· Recrutement
  • Burke Pharmaceutical Research
    Code postal vérifié
    Hot Springs, United States· Actif, mais pas en recrutement
  • Doc1 Healthcare Systems
    Code postal vérifié
    Brea, United States· Recrutement
  • California Dermatology & Clinical Research Institute
    Code postal vérifié
    Encinitas, United States· Actif, mais pas en recrutement
  • Marvel Clinical Research
    Code postal vérifié
    Huntington Beach, États-Unis· Actif, mais pas en recrutement
  • University of California - Irvine
    Code postal vérifié
    Irvine, United States· Recrutement
  • Gavin Herbert Eye Institute
    Code postal vérifié
    Irvine, United States· Recrutement
  • Southern California Clinical Research
    Code postal vérifié
    Santa Ana, United States· Actif, mais pas en recrutement
  • Brett King MD, LLC
    Code postal vérifié
    Fairfield, United States· Recrutement
  • Alliance for Multispecialty Research, LLC
    Code postal vérifié
    Fort Myers, United States· Actif, mais pas en recrutement

Questions fréquentes

Qu'est-ce que l'alopécie areata ?

Alopecia areata is a condition where your immune system attacks your hair follicles, leading to patches of hair loss on your scalp, face, and sometimes other parts of your body.

What is ritlecitinib?

Ritlecitinib is a type of medicine designed to help calm the immune system's activity that causes hair loss in alopecia areata.

Qu'est-ce qu'un placebo ?

A placebo is a dummy pill that looks exactly like the study medicine but doesn't contain any active drug. It helps researchers compare the real medicine's effects.

Combien de temps vais-je participer à l'étude ?

If you join, you'll be part of the study for about 13 months, with up to 9 visits to the clinic during that time.

Can I continue my other hair loss treatments?

No, if you join this study, you'll need to stop any other treatments you're currently taking for your alopecia areata.

Comment en savoir plus

Centre d'appel Pfizer CT.gov

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "A Study of 2 Doses of Ritlecitinib in People 12 Years of Age… vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.